Application Note
*Optimal dilutions/concentrations should be determined by the researcher.
Application |
Recommended Dilution |
1-2μg/ml |
Not tested in other applications.
Calculated MW
Positive Control
The peptide used to generate this antibody is available for purchase (GTX88068-PEP).
Form
Liquid
Buffer
TBS, 0.5% BSA
Preservative
0.02% Sodium azide
Storage
Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4ºC. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles.
Concentration
0.50 mg/ml (Please refer to the vial label for the specific concentration.)
Antigen Species
Human
Immunogen
Peptide with sequence C-KNPQLIIDTEKHHP, from the C Terminus (near) of the protein sequence according to NP_060322.1.
Purification
Purified by ammonium sulphate precipitation followed by antigen affinity chromatography
Conjugation
Unconjugated
Note
For laboratory research use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
Purchasers shall not, and agree not to enable third parties to, analyze, copy, reverse engineer or otherwise attempt to determine the structure or sequence of the product.
Synonyms
NLR family pyrin domain containing 2 , CLR19.9 , NALP2 , NBS1 , PAN1 , PYPAF2
Cellular Localization
Cytoplasm
Background
This gene is a member of the nucleotide-binding and leucine-rich repeat receptor (NLR) family, and is predicted to contain an N-terminal pyrin effector domain (PYD), a centrally-located nucleotide-binding and oligomerization domain (NACHT) and C-terminal leucine-rich repeats (LRR). Members of this gene family are thought to be important regulators of immune responses. This gene product interacts with components of the IkB kinase (IKK) complex, and can regulate both caspase-1 and NF-kB (nuclear factor kappa-light-chain-enhancer of activated B cells) activity. The pyrin domain is necessary and sufficient for suppression of NF-kB activity. An allelic variant (rs147585490) has been found that is incapable of blocking the transcriptional activity of NF-kB. Alternative splicing results in multiple transcript variants encoding different isoforms. [provided by RefSeq, Dec 2016]
Database
Research Area